Universitéde Montreal

Oric Pharmaceuticals, Inc.

Joanne Tan

Xiaohui Du

F Anthony Romero

Stephane Ciblat

Paul Gibbons

Jared Moore

Lea Constantineau-Forget

Hiroyuki Kawai

Kejia Wu

Michael Dore

Pierre Louis Beaulieu

Mukund Ghavre

Doris Schuetz

Eric Beaulieu

Yannick Rose

Daniel Gordon Michael Shore

Hugo De Almeida Silva

Dilan Emine Polat

Vincent Albert

Amit Nayyar

Hong Wang

Chudi Ndubaku

Jae Hyuk Chang

Jacques Banville

Sasmita Tripathy

Hugo Lavoie

Emeline Benoit

Compounds, compositions and their use in the treatment of a proliferative disease or condition such as a said proliferative disease or disorder is associated with a RAF gene mutation and/or a RAS gene mutation. The compounds disclosed are of Formula I or a pharmaceutically acceptable salt or solvate thereof, wherein R, R, R, X, X, Xand Xare as defined herein.

Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease

Disclosed herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, that are inhibitors of Polo Like Kinase 4 (PLK4). Also disclosed herein are pharmaceutical compositions comprising the compounds of Formula (I), or pharmaceutically acceptable salts thereof, and one or more pharmaceutically acceptable excipients. Further disclosed herein are methods of treating cancer in a subject in need thereof, comprising administering to the subject an amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

Polo like kinase 4 inhibitors

Compounds, compositions and their use in the treatment of a proliferative disease or condition such as a said proliferative disease or disorder is associated with a RAF gene mutation and/or a RAS gene mutation. The compounds disclosed are of Formula I or a pharmaceutically acceptable salt or solvate thereof, wherein R, R, R, X, X, Xand Xare as defined herein:

Growing community of inventors

San Mateo, CA, United States of America

Joanne Tan